David O’Malley, MD, discusses ongoing clinical trials evaluating immunotherapy in patients with advanced ovarian cancer.
David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center—The James, discusses ongoing clinical trials evaluating immunotherapy in patients with advanced ovarian cancer.
Multiple studies evaluating the addition of immunotherapy to frontline maintenance therapy are ongoing, says O’Malley. One of the largest trials being conducted in the United States is the 4-arm, phase III, placebo-controlled ATHENA trial. In the trial, patients are being randomized to receive either single-agent rucaparib (Rubraca), rucaparib plus nivolumab (Opdivo), nivolumab, or placebo in the maintenance setting.
Additionally, the phase III DUO-O trial is also ongoing. In the trial, patients with advanced disease are being randomized to receive chemotherapy plus durvalumab (Imfinzi) with or without bevacizumab (Avastin) followed by maintenance durvalumab, bevacizumab, and olaparib (Lynparza), concludes O’Malley.